109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
2015 至 2024 年溃疡性结肠炎 JAK 抑制剂研究趋势与热点：文献计量分析
Authors Wang Y, Wang Z , Lou P, Ni H, Yang Y, Chen G , Zhang S
Received 19 June 2025
Accepted for publication 30 September 2025
Published 17 October 2025 Volume 2025:18 Pages 6755—6771
DOI https://doi.org/10.2147/JMDH.S548268
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Charles V Pollack
Yifei Wang,1 Zhiying Wang,2 Pengfei Lou,1 Hong Ni,1 Yang Yang,1 Guangyao Chen,3,4 Shuxin Zhang1
1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 2General Office, Health Commission of Yubei District, Chongqing, People’s Republic of China; 3Department of TCM Rheumatology, China-Japan Friendship Hospital, Beijing, People’s Republic of China; 4Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Beijing, People’s Republic of China
Correspondence: Guangyao Chen, Email chenguangyao1994@163.com Shuxin Zhang, Email zhshxincn@126.com
Objective: To systematically investigate international trends and dynamics in research on Janus kinase (JAK) inhibitor applications for ulcerative colitis (UC) management over the past decade (2015– 2024) and delineate current research frontiers.
Methods: Publications was retrieved from the Web of Science core collection database and subjected to bibliometric analysis. VOSviewers, CiteSpace, Scimago Graphica, and Excel were used to conduct this bibliometric analysis and visualization.
Results: A total of 696 articles were included. Publication output exhibited an overall upward trajectory. The United States ranked first in global publication volume and served as the central hub for multiple extensive collaborative networks. Inflammatory Bowel Diseases published the highest number of relevant studies. William J. Sandborn emerged as the most academically influential scholar. Both reference and keyword analyses revealed that early research (pre-2018) focused on clinical efficacy validation and drug development of JAK inhibitors, while post-2018 studies shifted toward systematic evaluations of efficacy and safety, integration of clinical practice guidelines, and development of novel subtype selective JAK inhibitors.
Conclusion: This study delineates the evolution of JAK inhibitor research in UC over the past decade. Future efforts should prioritize strengthening global collaboration, advancing novel subtype selective JAK inhibitors, generating long-term safety data from clinical trials, and optimizing patient-stratified treatment strategies to address unmet therapeutic needs.
Keywords: Janus kinase inhibitor, ulcerative colitis, bibliometric analysis, research trends
1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 2General Office, Health Commission of Yubei District, Chongqing, People’s Republic of China; 3Department of TCM Rheumatology, China-Japan Friendship Hospital, Beijing, People’s Republic of China; 4Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Beijing, People’s Republic of China
Correspondence: Guangyao Chen, Email chenguangyao1994@163.com Shuxin Zhang, Email zhshxincn@126.com
Objective: To systematically investigate international trends and dynamics in research on Janus kinase (JAK) inhibitor applications for ulcerative colitis (UC) management over the past decade (2015– 2024) and delineate current research frontiers.
Methods: Publications was retrieved from the Web of Science core collection database and subjected to bibliometric analysis. VOSviewers, CiteSpace, Scimago Graphica, and Excel were used to conduct this bibliometric analysis and visualization.
Results: A total of 696 articles were included. Publication output exhibited an overall upward trajectory. The United States ranked first in global publication volume and served as the central hub for multiple extensive collaborative networks. Inflammatory Bowel Diseases published the highest number of relevant studies. William J. Sandborn emerged as the most academically influential scholar. Both reference and keyword analyses revealed that early research (pre-2018) focused on clinical efficacy validation and drug development of JAK inhibitors, while post-2018 studies shifted toward systematic evaluations of efficacy and safety, integration of clinical practice guidelines, and development of novel subtype selective JAK inhibitors.
Conclusion: This study delineates the evolution of JAK inhibitor research in UC over the past decade. Future efforts should prioritize strengthening global collaboration, advancing novel subtype selective JAK inhibitors, generating long-term safety data from clinical trials, and optimizing patient-stratified treatment strategies to address unmet therapeutic needs.
Keywords: Janus kinase inhibitor, ulcerative colitis, bibliometric analysis, research trends